Research Developments in Rheumatoid Arthritis

To participate in this activity, please:

The past decade has provided numerous advances in the treatment of rheumatoid arthritis. As will be discussed, recent evidence of 2 medications from different classes provide reassurance as to their long-term safety and efficacy. Of key importance is that these treatment advances provide a real opportunity to achieve disease remission using a treat-to-target approach. The benefits of achieving long-term disease remission vs low disease activity are presented. Join Dr. Roy Fleischmann as he discusses this recent evidence from the American College of Rheumatology Convergence 2020 virtual annual meeting and the implications for clinical practice.

Course Credit:

0.75 AMA PRA Category 1 CreditTM

Dates:

Opens: 2020-11-30
Closes: 2021-11-30

Target Audience:

This activity is intended for rheumatologists, primary care physicians, and other healthcare providers who manage patients with rheumatoid arthritis.

This activity is supported by an educational grant from Sanofi Genzyme.
  • Roy M. Fleischmann, MD

    Clinical Professor of Medicine
    University of Texas Southwestern Medical Center
    Medical Director
    Metroplex Clinical Research Center
    Dallas, Texas

Learning Objectives

  • Summarize the latest research developments in the treatment of rheumatoid arthritis
  • Describe how new data and recommendations can impact clinical practices to improve care
  • Incorporate evidence-based research into clinical practice

Faculty Disclosures

Roy M. Fleischmann, MD

Consultant: AbbVie, Amgen, Eli Lilly, GSK, Pfizer, UCB

Research Support: AbbVie, Amgen, BMS, Eli Lilly, GSK, Pfizer, Sanofi, TEVA, UCB


Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.75 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.